Biohaven

BHVN - Biohaven • Financials

Biohaven Ltd is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of life-changing treatments in key therapeutic areas, including immunology, neuroscience, and oncology. Its product pipeline includes Glutamate, Myostatin, Ion channels, Inflammation & Immunology, and Oncology. The company's products target diseases such as neuromuscular and metabolic diseases, antibody-drug conjugates for cancer, obsessive-compulsive disorder, and others.

Complete and updated financials table with all primary indicators: Net Income, Revenue, EBITDA, Margin, ROE, Dividends

Year
12/2020
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
12/2021
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
12/2022
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
12/2023
0
-429
-
0%
L
428
L
-382
-
-361
-3
212
-364
0
0
-
-
12/2024
0
-877
-
0%
L
-1,346
L
-486
-
-818
-4
678
-822
0
0
-
-
12/2025
0
-735
-
0%
L
-2,076
L
-80
-
-722
0
439
-722
0
0
-
-